Fw: Re: Fw: How to measure success with Provenge

[Guest guest]

He may be retiring, but he won't be going away or become incognito. He is capable of answering some questions about an article he wrote and his involvement in the recruitment of patients for the Provenge trial. He retired once before just before Harry Pinchot passed away but he came back. Maybe he will get bored and come back again. In any case I would think that he would be glad to explain what he knows. My opinion of course. Thanks for the heads up on his second retirement. Maybe like an aging rock musician he may want to do a farewell tour and another comeback. Just kidding.

I have not kept up with PCRI so I was unawares that he had relenquished any responsibility for it . But I do think that the current editors would be more than happy to allow him to make a few guest appearances and write some articles that will resolve whatever confusion still lingers with regards to Provenge. Providing of course that he wants to. He may even want to write a few articles on his vision on the future course of the field of immunotherapy in general. I would like to read it if he is willing to write it.

Regards, BOB.

> Not sure I can actually answer your question but the best place> to start is to get a hold of an issue of Dr. Strum's PCRI in> which he dedicated it almost entirely to the recruitment of> patients for the first Phase III clinical trial of Provenge.Small correction: Dr. Strum has not been associated with PCRI for several years.His former partner, Dr. Scholz, is Director.Regards,Steve JPS: Dr. Strum has announced his retirement at the end of the year. He deserves a rest, but it is a loss to so many who rely upon his wisdom.